Gastric CancerNCT05186402
Predictive Factors of Morbidity and Mortality and Overall Survival of Patients With Gastric Cancer : a Case Series
An observational study of Gastric Cancer and Mortality of Gastric Cancer, run by Sylvestre KABURA.
Trial summary
This is a retrospective study extending over a period of three years concerning patients with gastric adenocarcinoma hospitalized in the digestive cancer surgery and liver transplant service of the IBN ROCHD University Hospital Center in Casablanca. Read more about this study
- Who is it for?
- Ages 15 years and older
- Conditions the study is for
- Gastric Cancer, Mortality of Gastric Cancer, Overall Survival of Patients With Gastric Cancer
- What is being tested?
- Total or subtotal gastrectomy
- Type of treatment
- Surgery or procedure
- How many people
- 80 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 2016to 31 Dec 2018
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: The study enrolled all the patients who underwent gastric resection for gastric adenocarcinoma
Who may be able to join
- patients with gastric cancer
Who cannot join
- patients with benign tumors or other pathologies requiring gastric resection
About this study
This is a retrospective study extending over a period of three years concerning patients with gastric adenocarcinoma hospitalized in the digestive cancer surgery and liver transplant service of the IBN ROCHD University Hospital Center in Casablanca. Evaluation from a series of 80 cases of gastric adenocarcinomas, follow-up to determine the prognostic factors influencing mortality, morbidity and survival.
- Conditions
- Gastric Cancer, Mortality of Gastric Cancer, Overall Survival of Patients With Gastric Cancer
- Being tested
- Total or subtotal gastrectomy
- Keywords
- gastric cancer mortality, gastric cancer treatment
- Medical subject headings
- Stomach Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Total or subtotal gastrectomyProcedure or surgery
Also called Adjuvent chemotherapy
Gastric resection with digestive continuity according Roux or Bilroth
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall survival
An overall survival of patients treated for gastric cancer
Measured: 30 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jan 2022
- Study start1 Jan 2016
- Primary completion31 Dec 2018
- Study completion31 Dec 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gastric CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 80 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sylvestre KABURA
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Sylvestre KABURA, Centre Hospitalier Universitaire Ibn Rochd
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05186402
- Sponsor's protocol ID
- SKAHM2022
- Status last verified
- Dec 2021
- First submitted
- 27 Dec 2021
- Last updated
- 11 Jan 2022
- Results posted
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 11 Jan 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Predictive Factors of Morbidity and Mortality and Overall Survival of Patients With Gastric Cancer : a Case Series
- ClinicalTrials.gov ID
- NCT05186402
- Acronym / sponsor ID
- SKAHM2022
- Conditions
- Gastric Cancer, Mortality of Gastric Cancer, Overall Survival of Patients With Gastric Cancer
- Keywords
- gastric cancer mortality, gastric cancer treatment
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 80 participants (actual)
- Lead sponsor
- Sylvestre KABURAUniversity, hospital or other
- Study start
- 1 Jan 2016 (actual)
- Primary completion
- 31 Dec 2018 (actual)
- Study completion
- 31 Dec 2018 (actual)
- First posted
- 11 Jan 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a retrospective study extending over a period of three years concerning patients with gastric adenocarcinoma hospitalized in the digestive cancer surgery and liver transplant service of the IBN ROCHD University Hospital Center in Casablanca. Evaluation from a series of 80 cases of gastric adenocarcinomas, follow-up to determine the prognostic factors influencing mortality, morbidity and survival.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Ages
- 15 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- The study enrolled all the patients who underwent gastric resection for gastric adenocarcinoma
Key inclusion criteria (1 listed)
- patients with gastric cancer
Key exclusion criteria (1 listed)
- patients with benign tumors or other pathologies requiring gastric resection
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Total or subtotal gastrectomyAlso: Adjuvent chemotherapyGastric resection with digestive continuity according Roux or Bilroth | Procedure or surgery | – |
Primary outcome
Overall survival
Time frame: 30 months
An overall survival of patients treated for gastric cancer
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Jan 2022.
- Individual participant dataSharing planned: Undecided
Related trials for Gastric Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
Not yet recruitingPhase 1
GK01 Cell Therapy in Gastric Cancer With Peritoneal Metastasis
Gastric Cancer (GC)
RecruitingPhase 3
A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC.
Gastric, Esophagogastric Junction
Active, not recruitingEarly Phase 1
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
B-ALL, DLBCL
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Gastric Cancer and Mortality of Gastric Cancer, run by Sylvestre KABURA.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Jan 2022. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall survival (time frame: 30 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jan 2022.